Compare Expedia Group Inc (EXPE) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Illumina, Inc. — how do they compare? Expedia Group Inc trades at $269.5 (market cap $32.42B), while Illumina, Inc. trades at $265 (market cap $39.95B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Expedia Group Inc pays a 0.71% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and Illumina, Inc. for 83 Days on average.
| EXPE | ILMN | |
|---|---|---|
Market Cap | $32.42B | $39.95B |
Volume | 1,940,671 | 3,169,503 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $293.69 |
52-Week Low | $188.51 | $91.00 |
Typical Hold Time | 48 Days | 83 Days |
Enterprise Value | $30.98B | $41.31B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, with technical indicators showing bearish momentum as the stock tests key support levels. Fundamentally, the company demonstrates strong revenue growth from $14.73B in 2025 to projected $15.7B in 2026, with net income margins improving to 12.97%. Recent earnings beats and a 47.37% analyst buy rating support the positive outlook, though competition from AI travel agents presents headwinds.
The stock offers significant upside to the $335.06 consensus price target, representing 29% potential appreciation. Strong cash flow generation and improving profitability metrics support the bullish case, but investors must monitor competitive threats from AI disruption and recent layoffs indicating operational challenges. The current valuation at 16.28 P/E appears reasonable given growth prospects.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
